EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 30 / No 10 (Octobre 2014) Med Sci (Paris), 30 10 (2014) 864-873 References
Free Access
Issue
Med Sci (Paris)
Volume 30, Number 10, Octobre 2014
Page(s) 864 - 873
Section M/S Revues
DOI https://doi.org/10.1051/medsci/20143010013
Published online 14 October 2014
  1. Cooper CS, Park M, Blair DG, et al. Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature 1984 ; 311 : 29–33. [CrossRef] [PubMed] [Google Scholar]
  2. Nakamura T, Nawa K, Ichihara A. Partial purification and characterization of hepatocyte growth factor from serum of hepatectomized rats. Biochem Biophys Res Commun 1984 ; 122 : 1450–1459. [CrossRef] [PubMed] [Google Scholar]
  3. Stoker M, Gherardi E, Perryman M, Gray J. Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. Nature 1987 ; 327 : 239–242. [CrossRef] [PubMed] [Google Scholar]
  4. Weidner KM, Arakaki N, Hartmann G, et al. Evidence for the identity of human scatter factor and human hepatocyte growth factor. Proc Natl Acad Sci USA 1991 ; 88 : 7001–7005. [CrossRef] [Google Scholar]
  5. Gherardi E, Birchmeier W, Birchmeier C, Woude GV. Targeting MET in cancer: rationale and progress. Nat Rev Cancer 2012 ; 12 : 89–103. [CrossRef] [PubMed] [Google Scholar]
  6. Gherardi E, Youles ME, Miguel RN, et al. Functional map and domain structure of MET, the product of the c-met protooncogene and receptor for hepatocyte growth factor/scatter factor. Proc Natl Acad Sci USA 2003 ; 100 : 12039–12044. [CrossRef] [Google Scholar]
  7. Schiering N, Knapp S, Marconi M, et al. Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-Met and its complex with the microbial alkaloid K-252a. Proc Natl Acad Sci USA 2003 ; 100 : 12654–12659. [CrossRef] [Google Scholar]
  8. Gherardi E, Sandin S, Petoukhov MV, et al. Structural basis of hepatocyte growth factor/scatter factor and MET signalling. Proc Natl Acad Sci USA 2006 ; 103 : 4046–4051. [CrossRef] [Google Scholar]
  9. Andermarcher E, Surani MA, Gherardi E. Co-expression of the HGF/SF and c-met genes during early mouse embryogenesis precedes reciprocal expression in adjacent tissues during organogenesis. Dev Genet 1996 ; 18 : 254–266. [CrossRef] [PubMed] [Google Scholar]
  10. Uehara Y, Minowa O, Mori C, et al. Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor. Nature 1995 ; 373 : 702–705. [CrossRef] [PubMed] [Google Scholar]
  11. Schmidt C, Bladt F, Goedecke S, et al. Scatter factor/hepatocyte growth factor is essential for liver development. Nature 1995 ; 373 : 699–702. [CrossRef] [PubMed] [Google Scholar]
  12. Bladt F, Riethmacher D, Isenmann S, et al. Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud. Nature 1995 ; 376 : 768–771. [CrossRef] [PubMed] [Google Scholar]
  13. Calvi C, Podowski M, Lopez-Mercado A, et al. Hepatocyte growth factor, a determinant of airspace homeostasis in the murine lung. PLoS Genet 2013 ; 9 : e1003228. [CrossRef] [PubMed] [Google Scholar]
  14. Lamballe F, Genestine M, Caruso N, et al. Pool-specific regulation of motor neuron survival by neurotrophic support. J Neurosci 2011 ; 31 : 11144–11158. [CrossRef] [PubMed] [Google Scholar]
  15. Huh CG, Factor VM, Sanchez A, et al. Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair. Proc Natl Acad Sci USA 2004 ; 101 : 4477–4482. [CrossRef] [Google Scholar]
  16. Maina F, Casagranda F, Audero E, et al. Uncoupling of Grb2 from the Met receptor in vivo reveals complex roles in muscle development. Cell 1996 ; 87 : 531–542. [CrossRef] [PubMed] [Google Scholar]
  17. Royal I, Lamarche-Vane N, Lamorte L, et al. Activation of cdc42, rac, PAK, and rho-kinase in response to hepatocyte growth factor differentially regulates epithelial cell colony spreading and dissociation. Mol Biol Cell 2000 ; 11 : 1709–1725. [CrossRef] [PubMed] [Google Scholar]
  18. Moumen A, Ieraci A, Patane S, et al. Met signals hepatocyte survival by preventing Fas-triggered FLIP degradation in a PI3k-Akt-dependent manner. Hepatology 2007 ; 45 : 1210–1217. [CrossRef] [PubMed] [Google Scholar]
  19. Furlan A, Stagni V, Hussain A, et al. Abl interconnects oncogenic Met and p53 core pathways in cancer cells. Cell Death Differ 2011 ; 18 : 1608–1616. [CrossRef] [PubMed] [Google Scholar]
  20. Peschard P, Fournier TM, Lamorte L, et al. Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein. Mol Cell 2001 ; 8 : 995–1004. [CrossRef] [PubMed] [Google Scholar]
  21. Hashigasako A, Machide M, Nakamura T, Matsumoto K. Bi-directional regulation of Ser-985 phosphorylation of c-met via protein kinase C and protein phosphatase 2A involves c-Met activation and cellular responsiveness to hepatocyte growth factor. J Biol Chem 2004 ; 279 : 26445–26452. [CrossRef] [PubMed] [Google Scholar]
  22. Tulasne D, Deheuninck J, Lourenco FC, et al. Proapoptotic function of the MET tyrosine kinase receptor through caspase cleavage. Mol Cell Biol 2004 ; 24 : 10328–10339. [CrossRef] [PubMed] [Google Scholar]
  23. Ancot F, Leroy C, Muharram G, et al. Shedding-generated Met receptor fragments can be routed to either the proteasomal or the lysosomal degradation pathway. Traffic 2012 ; 13 : 1261–1272. [CrossRef] [PubMed] [Google Scholar]
  24. Kermorgant S, Parker PJ. Receptor trafficking controls weak signal delivery: a strategy used by c-Met for STAT3 nuclear accumulation. J Cell Biol 2008 ; 182 : 855–863. [CrossRef] [PubMed] [Google Scholar]
  25. Trusolino L, Bertotti A, Comoglio PM. A signaling adapter function for alpha6beta4 integrin in the control of HGF-dependent invasive growth. Cell 2001 ; 107 : 643–654. [CrossRef] [PubMed] [Google Scholar]
  26. Liu Y, Chattopadhyay N, Qin S, et al. Coordinate integrin and c-Met signaling regulate Wnt gene expression during epithelial morphogenesis. Development 2009 ; 136 : 843–853. [CrossRef] [PubMed] [Google Scholar]
  27. Orian-Rousseau V, Morrison H, Matzke A, et al. Hepatocyte growth factor-induced Ras activation requires ERM proteins linked to both CD44v6 and F-actin. Mol Biol Cell 2007 ; 18 : 76–83. [CrossRef] [PubMed] [Google Scholar]
  28. Sadanandam A, Rosenbaugh EG, Singh S, et al. Semaphorin 5A promotes angiogenesis by increasing endothelial cell proliferation, migration, and decreasing apoptosis. Microvasc Res 2010 ; 79 : 1–9. [CrossRef] [PubMed] [Google Scholar]
  29. Wang X, DeFrances MC, Dai Y, et al. A mechanism of cell survival: sequestration of Fas by the HGF receptor Met. Mol Cell 2002 ; 9 : 411–421. [CrossRef] [PubMed] [Google Scholar]
  30. Schmidt L, Duh FM, Chen F, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 1997 ; 16 : 68–73. [CrossRef] [PubMed] [Google Scholar]
  31. Joffre C, Barrow R, Menard L, et al. A direct role for Met endocytosis in tumorigenesis. Nat Cell Biol 2011 ; 13 : 827–837. [CrossRef] [PubMed] [Google Scholar]
  32. Jeffers M, Fiscella M, Webb CP, et al. The mutationally activated Met receptor mediates motility and metastasis. Proc Natl Acad Sci USA 1998 ; 95 : 14417–14422. [CrossRef] [Google Scholar]
  33. Graveel C, Su Y, Koeman J, et al. Activating Met mutations produce unique tumor profiles in mice with selective duplication of the mutant allele. Proc Natl Acad Sci USA 2004 ; 101 : 17198–17203. [CrossRef] [Google Scholar]
  34. Ponzetto C, Giordano S, Peverali F, et al. c-met is amplified but not mutated in a cell line with an activated met tyrosine kinase. Oncogene 1991 ; 6 : 553–559. [PubMed] [Google Scholar]
  35. Natali PG, Prat M, Nicotra MR, et al. Overexpression of the met/HGF receptor in renal cell carcinomas. Int J Cancer 1996 ; 69 : 212–217. [CrossRef] [PubMed] [Google Scholar]
  36. Ian M, Bond JA, Prat M, et al. Activated ras and ret oncogenes induce over-expression of c-met (hepatocyte growth factor receptor) in human thyroid epithelial cells. Oncogene 1997 ; 14 : 2417–2423. [CrossRef] [PubMed] [Google Scholar]
  37. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007 ; 316 : 1039–1043. [CrossRef] [PubMed] [Google Scholar]
  38. Bardelli A, Corso S, Bertotti A, et al. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov 2013 ; 3 : 658–673. [CrossRef] [PubMed] [Google Scholar]
  39. Morotti A, Mila S, Accornero P, et al. K252a inhibits the oncogenic properties of Met, the HGF receptor. Oncogene 2002 ; 21 : 4885–4893. [CrossRef] [PubMed] [Google Scholar]
  40. Christensen JG, Schreck R, Burrows J, et al. A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res 2003 ; 63 : 7345–7355. [PubMed] [Google Scholar]
  41. Gridelli C, Peters S, Sgambato A, et al. ALK inhibitors in the treatment of advanced NSCLC. Cancer Treat Rev 2013 ; 40 : 300–306. [CrossRef] [PubMed] [Google Scholar]
  42. Prat M, Crepaldi T, Pennacchietti S, et al. Agonistic monoclonal antibodies against the Met receptor dissect the biological responses to HGF. J Cell Sci 1998 ; 111 : 237–247. [PubMed] [Google Scholar]
  43. Merchant M, Ma X, Maun HR, et al. Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent. Proc Natl Acad Sci USA 2013 ; 110 : E2987–E2996. [CrossRef] [Google Scholar]
  44. Foveau B, Ancot F, Leroy C, et al. Downregulation of the Met receptor tyrosine kinase by presenilin-dependent regulated intramembrane proteolysis. Mol Biol Cell 2009 ; 20 : 2494–2506. [CrossRef] [Google Scholar]
  45. Matsumoto K, Nakamura T, Sakai K, Nakamura T. Hepatocyte growth factor and Met in tumor biology and therapeutic approach with NK4. Proteomics 2008 ; 8 : 3360–3370. [CrossRef] [PubMed] [Google Scholar]
  46. Coxon A, Rex K, Meyer S, et al. Soluble c-Met receptors inhibit phosphorylation of c-Met and growth of hepatocyte growth factor: c-Met-dependent tumors in animal models. Mol Cancer Ther 2009 ; 8 : 1119–1125. [CrossRef] [PubMed] [Google Scholar]
  47. Cepero V, Sierra JR, Corso S, et al. MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors. Cancer Res 2010 ; 70 : 7580–7590. [CrossRef] [PubMed] [Google Scholar]
  48. Bodmer A, Goetsch L, Laurence Favet L, et al. Anticorps et tumeurs solides. Cibles établies et pistes prometteuses. Med Sci (Paris) 2009 ; 25 : 1090–1098. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  49. Furne C, Mehlen P. Les radeaux de la mort : quand les radeaux lipidiques régulent les récepteurs à dépendance. Med Sci (Paris) 2006 ; 22 : 909–910. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.